Oligomerix is discovering and developing therapeutics for neurodegenerative diseases characterized by the accumulation of tau aggregates. By targeting tau self-association at the beginning of the tau cascade, our lead compound has shown in multiple animal models to prevent down stream tau degradation. There are over 20 tauopathies with a tau etiology with Alzheimer’s being the most prevalent.
Alzheimer’s disease is a degenerative brain disease and the most common form of dementia. It is estimated that more than 5.8 million Americans currently have AD (projected to be 14 million by 2050). AD remains a major unmet medical need. It is the most costly disease in the US with a financial burden of over of $305 billion (projected to be $1.1 trillion by 2050) to our nation (Alzheimer’s Association 2020 Alzheimer’s Disease Facts and Figures). Early and accurate diagnosis and treatment has been projected to save up to $7.6 trillion in medical and care costs.
Given the significant unmet needs across AD and related tauopathies, Oligomerix is focused on developing disease-modifying treatments across two key programs. The Company’s lead molecule program is progressing through its remaining preclinical toxicology studies with a primary focus on initiating Ph1a clinical studies for AD. We are also developing an additional program with the lead molecule to assess early target engagement in a Ph1b study in one of the rare disease tauopathies.
Furthermore, the Company has recently begun to characterize its 2nd generation series of small molecule tau aggregation inhibitors.The Company has also developed antibody fragments that are specific for tau oligomers. These antibodies can be used as biomarkers for the drug development programs and have potential for diagnostic and therapeutic development.